NIKTIMVO
Generic: axatilimab-csfr
- NDC
- 50881-012
- RxCUI
- 2691534
- Route
- INTRAVENOUS
- ICD-10 indication
- D89.811
Affordability Check
How much will you actually pay for NIKTIMVO?
In 30 seconds, see every legitimate way to afford NIKTIMVO — Medicare copay, manufacturer copay card, Patient Assistance Program, grants, or cash.
About NIKTIMVO
What is this medication?
Niktimvo is a prescription medicine used to treat chronic graft-versus-host disease in adults and pediatric patients who weigh at least 40 kilograms. It is specifically intended for individuals who have already received at least two prior lines of systemic therapy that did not effectively manage their condition. Chronic graft-versus-host disease is a complex immune response that can occur after a person receives a stem cell or bone marrow transplant, leading the donor cells to attack the recipient tissues and organs.
As a monoclonal antibody, this medication works by binding to and blocking the colony-stimulating factor 1 receptor. This action helps to reduce the activity and presence of pro-inflammatory macrophages, which are immune cells that play a significant role in the inflammation and fibrosis seen in chronic graft-versus-host disease. The treatment is administered as an intravenous infusion by a healthcare provider, usually on a schedule of once every two weeks.
Copay & patient assistance
- Patient Copay Amount: As little as $15 per prescription
- Maximum Annual Benefit Limit: Not Publicly Available
- Core Eligibility Restrictions: Must have commercial health insurance; residents of the United States or Puerto Rico; must have a valid prescription for an FDA-approved or compendia-recognized use. Patients insured through government programs (including Medicare Part B, Medicare Advantage, Medicaid, TRICARE, or any state medical/pharmaceutical assistance program) are not eligible. Uninsured, cash-paying, or Alternate Funding Program (AFP) patients are not eligible.
- RxBIN, PCN, and Group numbers: Not Publicly Available
External links go directly to the manufacturer's portal. RxCopays does not receive compensation for referrals.
Compare pricing elsewhere
RxCopays doesn't sell drugs or take referral fees. Here are the transparent-pricing directories we recommend checking alongside your insurance formulary.
Cost Plus Drug Company
Mark Cuban's transparent-pricing pharmacy — manufacturer cost + 15% markup + $5 dispensing fee. No insurance needed. Search alphabetically for axatilimab-csfr.
Browse Cost Plus medications →
GoodRx
Compare local pharmacy prices with GoodRx coupons. Use the price with your insurance or without — whichever is cheaper.
Lookup NIKTIMVO →
NeedyMeds
Independent nonprofit directory of patient assistance programs, copay cards, and charity co-pay foundations.
Search for axatilimab-csfr →
RxAssist
PAP directory maintained by Volunteers in Health Care at Brown University. Free, no ads.
Search PAPs →
We deep-link because transparency helps patients. None of these partners pay RxCopays.
Conditions we've indexed resources for
Click a condition to see copay cards, grants, and PA rules specific to it. For the full list of FDA-approved indications, see Prescribing information above.
Prior authorization & coverage
| Payer | PA | Step therapy | Copay tier |
|---|---|---|---|
— Medicare Part D | — | — | — |
Related drugs
How this page is sourced
- Drug identity verified against openFDA NDC Directory.
- Label text (when shown) originates from NLM DailyMed.
- Copay and assistance URLs verified periodically; if you hit a broken link, tell us.
Rare-disease navigation (specialists, trials, patient communities)
NIKTIMVO treats a rare condition. For in-depth disease pages on our sister site:
UniteRare.org is our sister site for rare-disease navigation — same editorial team, same accuracy standards.